- The trend backdrop is active with a 16-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is constructive, supporting the smart-money activity read.
TKD
VIE
Week ended 07 Aug 2026
Weekly Investor Report
Takeda Pharmaceutical Company Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
30.18 EUR
1.2%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 580.6% above the Trend Line and sits at 40.0% of its 52-week range. The latest completed week returned 1.2%, after a 4.6% four-week move. The latest news-sentiment score is 50/100.
Setup score
45
out of 100
Latest Close
30.18 EUR
7 Aug 2026
1W Return
1.2%
latest completed week
4W Return
4.6%
short-term follow-through
12W Return
5.3%
quarterly tape
Trend Breadth
44.2%
23 of 52 weeks active
Volume Ratio
-
vs 13-week average
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 44.16% based on similar historical setup states.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
Price follow-through
1.2%
Latest completed week; four-week move 4.6%.
Indicator stack
69/31
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 44.16%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
8 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 580.6% above the Trend Line and sits at 40.0% of its 52-week range. The latest completed week returned 1.2%, after a 4.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is - the 13-week average. Participation data is incomplete.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.8412-week average 0.79
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.84Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 4.6% over four weeks, 5.3% over 12 weeks, and -82.0% over one year. The current trend has remained active for 16 consecutive weeks.
Performance by holding period
Active trend streak16 weeks
Active weeks in one year23
Trend breadth44.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.24Latest activity-pressure read.
Pressure change-182.8%Four-week change in activity pressure.
Leadership404.73Latest relative-leadership reading.
RS change1145.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 8 relevant articles.
0 positive · 7 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-83.3%Distance below the 52-week high.
13-week volatility2.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+146.6%Week of 3 Apr.
Worst week-6.4%Week of 24 Apr.
Latest week+1.2%Week of 7 Aug.
Shape of recent returns
Strong gains2
Modest gains9
Flat weeks0
Modest losses13
Sharp losses2
Recent vol2.6%13-week weekly-return volatility.
Base vol27.6%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew8.7% / -6.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAT Healthcare
4-week rank37 / 100
Group average2.6%
Trend breadth47.0%
Trend47.0%active weekly trend signals
MD73.0%positive activity pressure
RS10.0%positive relative leadership
Four-week leaders
IndustryAT Drug Manufacturers - Specialty & Generic
4-week rank5 / 16
Group average-0.9%
Trend breadth50.0%
Trend50.0%active weekly trend signals
MD12.5%positive activity pressure
RS12.5%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape46/100
Trend, activity pressure, participation, and risk combine to a 46/100 tape read.
Indicator analysis74/100Latest 12-week confirmation: trend 12/12, activity pressure 9/12, relative leadership 6/12.
Activity pressure 0.84; No reversal markers Next-Week ExpectancyNegative 44.16%Next-week expectancy is negative with a 44.16% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 8 relevant articles.
Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 30.18 EUR | 1.2% | -6.28 EUR | -101.0 EUR | -0.24 | 404.73 | 0 | On |
| 31 Jul 2026 | 29.83 EUR | -2.5% | -9.35 EUR | -56.81 EUR | -0.28 | 209.10 | 0 | On |
| 24 Jul 2026 | 30.58 EUR | 2.8% | -12.31 EUR | -13.08 EUR | -0.17 | 124.43 | 0 | On |
| 17 Jul 2026 | 29.76 EUR | 3.2% | -15.28 EUR | 30.93 EUR | 0.05 | 71.82 | 0 | On |
| 10 Jul 2026 | 28.85 EUR | -0.6% | -18.15 EUR | 75.26 EUR | 0.29 | 32.51 | 0 | On |
| 3 Jul 2026 | 29.03 EUR | 4.5% | -20.92 EUR | 118.9 EUR | 0.60 | 10.45 | 0 | On |
| 26 Jun 2026 | 27.77 EUR | 3.8% | -23.71 EUR | 163.7 EUR | 0.79 | -7.48 | 10 | On |
| 19 Jun 2026 | 26.76 EUR | -3.0% | -26.48 EUR | 208.7 EUR | 0.91 | -23.52 | 0 | On |
| 12 Jun 2026 | 27.60 EUR | 1.9% | -29.20 EUR | 255.0 EUR | 1.04 | -27.01 | 0 | On |
| 5 Jun 2026 | 27.08 EUR | -1.4% | -31.94 EUR | 301.6 EUR | 1.15 | -33.93 | 0 | On |
| 29 May 2026 | 27.46 EUR | -0.8% | -34.57 EUR | 349.4 EUR | 1.25 | -39.75 | 0 | On |
| 22 May 2026 | 27.67 EUR | -3.5% | -37.23 EUR | 396.5 EUR | 1.34 | -42.82 | 0 | On |
| 15 May 2026 | 28.67 EUR | 1.1% | -39.95 EUR | 444.0 EUR | 1.41 | -44.10 | 0 | On |
| 8 May 2026 | 28.35 EUR | -1.3% | -42.70 EUR | 491.1 EUR | 1.45 | -48.71 | 0 | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.